刘明洋，中国医学科学院肿瘤医院分子肿瘤学全国重点实验室研究员，课题组长，医科院准聘助理教授，博士生导师，国家海外高层次青年人才，北京市杰青。以第一或通讯作者先后在Cancer Cell, Gastroenterology (五篇) , Journal of Clinical Investigation, Clinical Cancer Research, Cancer Research等杂志发表30余篇SCI论文。主持国自然基金面上项目等。现为Pancreas和Pancreatology杂志副主编，Cancer Letters杂志编委。现为中国抗癌协会青年理事会理事，中国医疗保健促进会胰腺病学分会常委，国际肝胆胰协会中国分会胰腺肿瘤专业常委。院校引进人才。

长期从事胰腺癌恶病质发生机制，化疗免疫耐药机制研究。发现巨噬细胞通过与肿瘤细胞互作促进胰腺癌细胞分泌恶病质因子，诱导肌肉萎缩和恶病质（Cancer Cell, 2025）; 发现胰腺癌细胞分泌miR-203a通过激活肌肉细胞内ZEB1-SLC11A2通路诱导肌肉铁死亡，促进肌肉萎缩（Cancer Letters, 2025）。在胰腺癌耐药方面，发现对化疗耐药的肿瘤细胞高表达ZEB1，通过去乙酰化CXCL16，抑制GZMA+CD8+T细胞的浸润，招募免疫抑制性中性粒细胞招募，降低肿瘤细胞对化疗药及anti-PD1的响应（Journal of Clinical Investigation, 2025）。

1. Zhang S#, Hu Y#, Zhou Z#, Lv G, Zhang C, Guo Y, Wang F, Ye Y, Qi H, Zhang H, Wu W, Li M*, Liu M*. ZEB1 promotes chemo-immune resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL16. J Clin Invest. 2025 Sep 9:e195970. (IF=13.6)

2. Hu Y#, Hu Y#, Zhang S#, Guo Y, Wang F, Du Y, Wang L, Li P, Xu Y, Zhang H, Yang Z, Liu Z, Xu J*, Liu M*. Tumor-derived miR-203a-3p potentiates muscle wasting by inducing muscle ferroptosis in pancreatic cancer. Cancer Lett. 2025 Apr 1;614:217523. (IF=9.1)

3. Liu M#, Ren Y#, Zhou Z#, Yang J#, Shi X#, Cai Y#, Arreola AX, Luo W, Fung KM, Xu C, Nipp RD, Bronze MS, Zheng L, Li YP, Houchen CW, Zhang Y*, Li M*. The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia.Cancer Cell. 2024 May 13;42(5):885-903.(IF=50.3)

4. Wu J #, Zhou J#, Li J#, Liu H#, Zhang H, Zhang J, Huang W, He Y, Zhu S, Huo M*, Liu M*, Zhang C*. CHD4 Promotes Acquired Chemoresistance and Tumor Progression by Activating MVP/ERK Axis. Drug Resist Updat. 2023 Jan;66:100913. (IF=24.3)

5. Liu M#, Zhang Y#, Yang J#, Zhan H#, Zhou Z, Jiang Y, Shi X, Luo W, Fung K, Xu C, Bronze M, Houchen CW, Li M*. Zinc Dependent Regulation of ZEB1 and YAP1 Co-activation Promotes EMT Plasticity and Metastasis in Pancreatic Cancer. Gastroenterology. 2021 Apr;160(5):1771-1783.(IF=22.682, C100)